GLP-1s after bariatric surgery: recurrence and a suboptimal response are different

Name the problem before comparing a treatment

Weight recurrence after an initial loss and a smaller-than-expected response after surgery are related, but different, research questions. The trial entry criteria can determine which one is being studied. I would begin a consultation by describing the surgery, the weight trajectory and the current concern without treating recurrence as a personal failure. A medication study cannot tell whether a particular patient needs nutritional review, investigation of symptoms, an anatomical assessment or another approach. The useful next step is an evaluation connected to the bariatric care team, rather than choosing a medication because its average result looks largest.

BARI-OPTIMISE studied a selected response group

BARI-OPTIMISE randomized 70 adults at least one year after gastric bypass or sleeve gastrectomy who had lost no more than 20% of body weight from surgery and had a suboptimal meal-stimulated GLP-1 response. At 24 weeks, estimated weight change was about minus 8.8% with liraglutide versus minus 0.5% with placebo. Both groups received lifestyle support. Gastrointestinal adverse events were more frequent with liraglutide. The specialized eligibility criteria matter: this was not a trial of every person requesting additional weight loss after surgery, and the medication-period baseline differed from the original surgical baseline.^[1]

The recurrence trial asked a different question

A separate 56-week randomized trial examined liraglutide after weight recurrence following Roux-en-Y gastric bypass. Average weight change favored liraglutide, with about 8.8% loss versus a 1.1% gain with placebo. The pandemic affected completion. Those findings should remain attached to the procedure, recurrence history and trial conditions. They do not establish that medication will replace revision surgery, identify who should receive either treatment or settle outcomes after other operations. I would keep the difference between weight recurrence and poor initial response visible when discussing which study is most relevant.^[2]

What the 2026 BARI-STEP trial contributes

BARI-STEP randomized 70 adults with less than 20% weight loss at least one year after gastric bypass or sleeve gastrectomy. Semaglutide or placebo was studied with lifestyle intervention over 68 weeks. The reported intention-to-treat sample included 63 participants; estimated weight change was minus 18.0% with semaglutide versus plus 0.4% with placebo. This is current randomized evidence in a selected post-surgical population. It remains a small trial, and serious adverse events occurred. A strong average weight effect should be considered alongside tolerability, follow-up and the limits of generalizing to an individual patient.^[3]

Keep the denominator beside every percentage

There are several possible starting points: weight before surgery, lowest weight after surgery, weight when medication begins and weight when follow-up ends. A percentage calculated from one cannot be compared directly with a percentage calculated from another. If you bring a study to an appointment, write its baseline beside the result. For your own record, preserve the dates and measured weights without trying to make your trajectory match a trial. This avoids the common mistake of presenting additional medication-period loss as the total benefit of surgery plus medicine, or calling a subgroup average a personal target. Our real-world versus trial results guide explains why study averages and an individual course can diverge.

Do not rank medicines by separate post-surgery trials

The liraglutide and semaglutide studies differed in eligibility, duration and design. A larger percentage in one does not establish head-to-head superiority in the same patients. It also does not answer whether a compounded preparation reproduces the studied treatment. I would look for a direct comparison before making a ranking claim, and keep approved-product evidence separate from commercial access options. The important practical question is which evaluation and follow-up are appropriate for you, not which study supplies the most attractive number for a comparison card. For product distinctions, read branded versus compounded GLP-1s before applying a trial result to an advertised package.

Ask who owns the post-surgical follow-up

If another clinician or telehealth service becomes involved, ask how it will coordinate records, symptom assessment and nutritional follow-up with the bariatric team. Write down who handles persistent vomiting, difficulty maintaining intake or other new problems, rather than assuming a general weight-loss membership covers every post-surgical need. This is a service-scope question that should be answered before payment. The trials demonstrate outcomes within defined clinical settings; they do not certify that an online intake recreates those settings. A provider’s availability and a patient’s suitability are separate decisions. Bring the operative history and any existing follow-up plan so a new clinician does not have to infer the procedure from a brief intake checkbox. Ask which records are essential and use a secure transfer route. That conversation is useful even if medication is ultimately not recommended.

Build a budget around the proposed care plan

Once the clinical plan is established, request the complete medication, consultation, laboratory and follow-up costs. Ask what happens if the medicine is not tolerated or another assessment becomes necessary, and avoid paying for a long commitment before understanding cancellation terms. I would compare care models on access and coordination as well as price. Research can inform that discussion, but it cannot promise that a commercial program will deliver the trial average or avoid further surgical care. Keep the clinical decision and the purchase decision connected without treating them as the same question. Our LifeMD review examines its published service and billing; confirm post-bariatric expertise directly. Use the complete GLP-1 cost checklist when comparing a proposed plan.

Explore relevant provider reviews

Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.

Continue your research

• GLP-1s and Parkinson’s: mixed trial results and an important 2026 notice
• GLP-1s before hip replacement: lower complication rates are not a timing rule
• Tirzepatide vs semaglutide for A1c: read SURPASS-2 separately from weight-loss trials